贝叶斯多变量网络Meta分析模型用于限制性平均生存时间差异
网络Meta分析(NMA)传统上依赖风险比与比例风险假设,并忽略试验间随访时长差异。本文提出一种新的多变量NMA模型,用于限制性平均生存时间(RMST)差异,同时合成多个时间点的证据,并通过研究内与跨研究协方差借用信息。模拟研究显示,多时间点模型在所有时间点的均方误差均低于传统单时间点模型,尤其在证据可用性降低时;在晚期非小细胞肺癌二线治疗随机试验网络中,该模型提高了精度并更早检测到获益证据。
要点
- 传统NMA依赖风险比与比例风险假设,忽略随访时长差异。
- 新模型多时间点合成RMST差异证据,模拟中均方误差更低。
- 肺癌网络示例中,多时间点模型精度提高且更早检测到获益。
核心结论
- 多时间点贝叶斯NMA模型可提供临床可解释的治疗效应度量,并在模拟与示例中优于单时间点模型。
研究设计与样本
- 方法学文章,提出多变量NMA模型并估计研究内协方差,在贝叶斯框架下估计,通过模拟研究评估,并在晚期非小细胞肺癌二线治疗随机试验网络中进行示例。
主要发现
- 模拟研究中,多时间点模型在所有时间点的均方误差均低于传统单时间点模型,尤其当证据可用性降低时。
- 在晚期非小细胞肺癌二线治疗随机试验网络中,多时间点模型较单时间点模型提高了精度,并在更早时间点检测到获益证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Network meta-analysis (NMA) is essential for clinical decision-making. NMA enables inference for all pair-wise comparisons between interventions available for the same indication, by using both direct evidence and indirect evidence. In randomized trials with time-to event outcome data, such as lung cancer data, conventional NMA methods rely on the hazard ratio and the proportional hazards assumption, and ignore the varying follow-up durations across trials. We introduce a novel multivariate NMA model for the difference in restricted mean survival times (RMST). Our model synthesizes all the available evidence from multiple time points simultaneously and borrows information across time points through within-study covariance and between-study covariance for the differences in RMST. We propose an estimator of the within-study covariance and we then assume it to be known. We estimate the model under the Bayesian framework. We evaluated our model by conducting a simulation study. Our multiple-time-point model yields lower mean squared error over the conventional single-time-point model at all time points, especially when the availability of evidence decreases. We illustrated the model on a network of randomized trials of second-line treatments of advanced non-small-cell lung cancer. Our multiple-time-point model yielded increased precision and detected evidence of benefit at earlier time points as compared to the single-time-point model. Our model has the advantage of providing clinically interpretable measures of treatment effects.
引用
- Tang X, Trinquart L. Bayesian multivariate network meta-analysis model for the difference in restricted mean survival times. Stat Med. 2021. PMID: 34883534. doi:10.1002/sim.9276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。